Bio-Rad Laboratories (NYSE: BIO)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Bio-Rad Laboratories Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Bio-Rad Laboratories Company Info
The Company manufactures and supplies the life science research, healthcare, analytical chemistry, and other markets with products and systems used to separate chemical and biological materials, and to identify analyze and purify their components.
News & Analysis
Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.
They are coming off strong quarters, yet appear to be underpriced based on their fundamentals. Is now a good time to buy?
Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.
There's a strong case to be made for both companies, but which one is a better investment?
Bio-Rad's Q4 revenue and earnings were disappointing, but its 2020 outlook looked good.
The company scored an important win in a patent dispute.
10X Genomics is growing revenue at a healthy clip, but a series of patent-infringement suits are hanging over the lab-hardware business.
BIO earnings call for the period ending September 30, 2021.
BIO earnings call for the period ending June 30, 2021.
BIO earnings call for the period ending March 31, 2021.
BIO earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.